Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Ortho synthesizes inhibitors of serine proteases

Feb. 18, 1997

COR Therapeutics discloses factor Xa inhibitors

Feb. 18, 1997

Comparative study of second-generation t-PA inhibitor and alteplase

Feb. 17, 1997

Anti-factor Xa compounds disclosed by RPR

Feb. 14, 1997

ZymoGenetics/Novo Nordisk isolate anticlotting agent

Feb. 14, 1997

FDA approves product for hemophilia

Feb. 13, 1997

Roberts receives approvable letter from FDA for Agrylin

Feb. 12, 1997

Potent gpIIb/IIIa antagonist synthesized using combinatorial techniques

Feb. 11, 1997

NIH funds development of antiplatelet agents from Cypress/PRP

Feb. 7, 1997

BASF discloses antithrombotic from ticks

Feb. 6, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.